Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), Novavax Inc. (NASDAQ:NVAX) and CRISPR Therapeutics AG (NASDAQ:CRSP) are trending on Thursday.
In pre-market trading, RXRX fell 1.42% to $3.45, CRSP dropped 0.15% to $59.72 and NVAX slipped 0.11% to $8.78.
Cancer Therapy Breakthrough Sparks Sector-Wide Rally
The surge follows Merck & Co. Inc. (NYSE:MRK) and Moderna Inc.‘s (NASDAQ:MRNA) Wednesday pre-market announcement of positive Phase 3 results for intismeran autogene, an individualized mRNA cancer therapy, combined with KEYTRUDA.
The trial, involving 1,137 melanoma patients, marked the first positive Phase 3 data for a neoantigen-based mRNA cancer treatment, according to the companies.
Recursion Draws Company-Specific Attention
Apart from the broader sector news, RXRX had its own catalyst. In a Wednesday Securities and Exchange Commission filing, former Recursion director Christopher C. Gibson disclosed plans to sell 100,000 Class A shares, worth roughly $327,500, through brokerage firm Fidelity Brokerage Services LLC.
Gibson has sold shares regularly since May.
Trading Metrics
| Stock | Market Cap | 52-Week Range | YTD Performance |
|---|---|---|---|
| NVAX | $1.45 Billion | $6.20–$11.97 | +23.28% |
| CRSP | $5.78 Billion | $44.12–$78.48 | +11.23% |
| Recursion | $1.87 Billion | $2.77–$7.18 | -16.67% |
On Wednesday, RXRX closed up 13.27% at $3.50, NVAX gained 10.84% to $8.79 and CRSP rose 12.91% to $59.81, according to Benzinga Pro data.
Benzinga’s Edge Stock Rankings indicate RXRX stock has a negative price trend across all time frames.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Spyro the Dragon on Shutterstock